Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565–0871, Japan.
Biol Pharm Bull. 2011;34(12):1835-40. doi: 10.1248/bpb.34.1835.
The development of a simple, easy-to-use, and non-invasive vaccination system is in high demand. For transcutaneous immunization (TCI), we previously developed a hydrogel patch formulation that accelerates the penetration of an antigen (Ag) through the stratum corneum (SC) and effectively elicits Ag-specific immune responses. The present studies were performed to optimize the composition and assess the safety of the patch formulation. A hydrogel patch with a water content ratio of 5% more effectively induced an immune response compared to patches with a different composition, suggesting that the moisture content of the hydrogel patch formulation has optimal ratio for SC hydration to promote Ag penetration through the SC. TCI using a hydrogel patch induced few local and systemic adverse reactions. Based on these results, we are now advancing translational research to evaluate the safety and efficacy of our novel TCI system in humans.
人们迫切需要开发一种简单、易用且非侵入性的疫苗接种系统。对于经皮免疫（TCI），我们之前开发了一种水凝胶贴剂配方，该配方可加速抗原（Ag）穿过角质层（SC）的渗透，并有效引发 Ag 特异性免疫反应。本研究旨在优化贴剂配方的组成并评估其安全性。与具有不同组成的贴剂相比，水含量比高 5%的水凝胶贴剂更有效地诱导免疫反应，这表明水凝胶贴剂配方的水分含量对于促进 Ag 通过 SC 渗透到 SC 中具有最佳比例。TCI 使用水凝胶贴剂引起的局部和全身不良反应很少。基于这些结果，我们正在推进转化研究，以评估我们新型 TCI 系统在人体中的安全性和有效性。
